Thank you for your write up Wehalls, I remain overall encouraged even though I am a bit deflated that the TGA route seems to be rapidly dwindling. More likely, it appears to be a probable dead end since we would not likely put limited resources into a foreign drug approval agency if a `fast track' avenue is not an option for us.
I always thought the ocular route with Miami would be our first revenue producer despite the statement that Management is "trying to stay focused and putting everything on the back burner that is not related to their current oncology trials". I forgot about the animal/pet possibility, glad to hear that is moving forward, I honestly thought that had great merit as well.
Don't know what to think about the reverse stock split, I do not recall one company off hand that has used it successfully; I realize there are certainly outliers. Sounds like Ed and Dom are not to concerned about financing, that is certainly positive news. And having potential investors helping out with clinical trials is very positive. I like the idea that any financial decision they make has at least some consideration for the shareholders. PHR has been wonderful to us so far, I think they are a stand up management team, no one else would finance a company like they do by buying the convertible shares over market value. Would just like to see some traction in clinical outcomes; just seems like a consistent one foot forward, another step backwards approach.
Appreciate your write-up, I remain pretty upbeat about the company despite knowing it remains a long shot for commercial success (inherent with the industry). One can dream though, and patients may one day may have medical options that can truly extend and improve quality of life thanks to PVCT. Thank you for your efforts.
